roflumilast analogs (Amakem Therapeutics)

N/A

Report date: 2025/03/20 20:00:06

NME

Base Information

Drug Nameroflumilast analogs (Amakem Therapeutics)

Drug Alias NameN/A

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionPhosphodieterase 4 inhibitors

TargetsPhosphodieterase 4

Therapy Area/IndicationsInflammationAutoimmune Diseases

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgium

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesAmakem Nv

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesAmakem Nv

Active IndicationsN/A

Inactive IndicationsInflammationAutoimmune Diseases

ATC CodeN/A